Results 251 to 260 of about 45,621 (284)

Impact of <i>CYP1A</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, <i>CYP3A4</i>, <i>CYP3A5</i>, and <i>NFIB</i> genotypes on clozapine serum concentration in smokers and nonsmokers. [PDF]

Ther Adv Psychopharmacol
Lenk HÇ, Bråten LS, Andreassen OA, Molden E.   +3 more
europepmc   +1 more source

A case report of drug-drug interaction between voriconazole and simnotrelvir/ritonavir. [PDF]

Front Antibiot
Chen T, Zhang Q.
europepmc   +1 more source

Therapeutic Drug Monitoring-Guided Antifungal Therapy Under Tyrosine Kinase Inhibitor Treatment in an Advanced Osteosarcoma Patient with Invasive Pulmonary Aspergillosis. [PDF]

Infect Drug Resist
Wen R, Ni W, Gu X, Liu B, Bai G, Zhang X.   +5 more
europepmc   +1 more source

Exposure-Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM. [PDF]

J Clin Pharmacol
Merali S, Bunn H, Sychterz C, Chiang M, Puli S, Sehnert AJ, Murthy B, Gobburu J.   +7 more
europepmc   +1 more source

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review. [PDF]

J Clin Med
Mansour GK, Altebainawi AF, Hajjar AW, Sayed SBH, Alazem FA, Sajid MR.   +5 more
europepmc   +1 more source

Population Genetics of Pharmacogenetic Variants in a Greek Psychiatric Cohort of over 3000 Individuals. [PDF]

Int J Mol Sci
Ntoumou E, Papailia S, Vrachnos DM, Fotis T, Salata E, Kapellou A, Vittas S.   +6 more
europepmc   +1 more source

Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participants. [PDF]

Drug Metab Dispos
Wu YP, Gelal A, Moon C, Metzger IF, Lu JBL, Callaghan JT, Skaar TC, Desta Z.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CYP2C19 gene polymorphism in Ningxia

Pharmacological Reports, 2023
Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for H.pylori infection in healthy people.We used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci ...
Zhen Yang, Yunqian Xie, Daya Zhang, Yan Zou, Ximei Li, Runxiang Chen, Xiaodong Zhang, Shiju Chen, Feihu Bai   +8 more
openaire   +2 more sources

The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta‐analysis

Mycoses (Berlin), 2021
Voriconazole primary metabolism is catalysed by CYP2C19. A large variability of trough concentrations in patients with invasive fungal infection treated with voriconazole has been observed in clinical practice.
Ying Zhang, K. Hou, Fang Liu, Xingxian Luo, Shiyu He, Lei Hu, Changqing Yang, Lin Huang, Yufei Feng   +8 more
semanticscholar   +1 more source